Sonoma Pharmaceuticals (SNOA) Revenue (2010 - 2026)

Sonoma Pharmaceuticals' Revenue history runs 17 years deep, the most recent figure standing at $5.6 million for Q1 2026.

• On a quarterly basis, Revenue rose 48.14% year-over-year to $5.6 million in Q1 2026; TTM through Mar 2026 was $19.5 million, a 36.68% increase from a year earlier, with the FY2026 full-year figure at $19.5 million, up 36.68% from the prior year.
• Revenue rose to $5.6 million in Q1 2026 per SNOA's latest filing, from $4.3 million in the prior quarter.
• Across five years, Revenue topped out at $5.6 million in Q3 2025 and bottomed at $2.3 million in Q1 2022.
• The 5-year median for Revenue is $3.4 million (2024), against an average of $3.7 million.
• Across the five-year window, Revenue decreased 18.01% in 2023 and soared 56.58% in 2025, its largest moves.
• Year by year, Revenue stood at $2.9 million in 2022, then gained by 6.59% to $3.1 million in 2023, then increased by 13.58% to $3.6 million in 2024, then gained by 22.03% to $4.3 million in 2025, then increased by 27.87% to $5.6 million in 2026.
• Per Business Quant, the three latest SNOA Revenue figures stand at $5.6 million (Q1 2026), $4.3 million (Q4 2025), and $5.6 million (Q3 2025).